Last reviewed · How we verify
Maintenance icotinib
Icotinib is a small-molecule tyrosine kinase inhibitor that selectively blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell proliferation.
Icotinib is a small-molecule tyrosine kinase inhibitor that selectively blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell proliferation. Used for Maintenance treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations.
At a glance
| Generic name | Maintenance icotinib |
|---|---|
| Also known as | Gemzar, DDP, Comana, BPI-2009 |
| Sponsor | Betta Pharmaceuticals Co., Ltd. |
| Drug class | EGFR tyrosine kinase inhibitor (TKI) |
| Target | EGFR (epidermal growth factor receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Icotinib irreversibly binds to and inhibits EGFR tyrosine kinase, preventing autophosphorylation and downstream signaling cascades that drive cell growth and survival in EGFR-dependent cancers. As a maintenance therapy, it is administered after initial chemotherapy or other treatments to sustain disease control and delay progression in patients with EGFR-mutant lung cancer.
Approved indications
- Maintenance therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations
Common side effects
- Rash/dermatitis
- Diarrhea
- Nausea
- Elevated liver enzymes
- Fatigue
- Anorexia
Key clinical trials
- Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations (PHASE3)
- Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer (PHASE2)
- Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients (PHASE3)
- Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma (PHASE3)
- Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation (PHASE2)
- Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma (PHASE4)
- Chemotherapy of NSCLC With or Without Icotinib (PHASE2)
- Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Maintenance icotinib CI brief — competitive landscape report
- Maintenance icotinib updates RSS · CI watch RSS
- Betta Pharmaceuticals Co., Ltd. portfolio CI